Equities

Hexima Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
HXL:ASX

Hexima Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.013
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change--
  • Beta1.1290
Data delayed at least 20 minutes, as of Oct 24 2024.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Hexima Limited is an Australia-based company. The Company is exploring opportunities for transactions with third parties which could enable the potential value of the Company’s assets, including its intellectual property.

  • Revenue in AUD (TTM)0.00
  • Net income in AUD-503.83k
  • Incorporated1997
  • Employees--
  • Location
    Hexima LtdLa Trobe Institute for Molecular ScienceLevel 4, LIMS2, La Trobe UniversityMELBOURNE 3086AustraliaAUS
  • Phone+61 39863-6477
  • Fax+61 38610-0599
  • Websitehttps://hexima.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Hexima Ltd0.00-503.83k2.17m-----------0.0246-0.02460.000.00910.00-------26.34-72.86-28.49-144.87-------335.94----0.00---100.00--46.05------
Argent BioPharma Ltd180.56k-17.84m4.56m--------25.24-0.3292-0.32920.0032-0.11960.02720.27210.4238---269.25-135.49---380.4224.06-45.51-9,882.75-764.450.1752-321.38-----79.74-38.66-1.79---70.28--
BPH Global Ltd352.38k-1.49m5.56m31.00------15.78-0.0026-0.00260.0006-0.00140.85483.492.27---360.76-76.32---214.326.8617.08-422.04-156.560.1995-43.14----220.43-13.5624.87------
Inhalerx Ltd837.55k-1.33m5.91m--------7.06-0.006-0.0060.0037-0.00410.8301--2.50---131.43-73.85---100.32-----158.33-369.19---------66.3821.6716.21------
Invion Ltd0.00-8.81m7.11m8.00--0.8538-----0.1183-0.11830.000.09720.00-------70.63-29.16-77.64-30.88-------147.34----0.00---100.00---56.50------
Vectus Biosystems Ltd18.77k-1.78m7.21m--------384.31-0.0334-0.03340.0004-0.00480.0134--0.0266---126.57-79.19-247.24-189.44-----9,468.62-10,165.010.9301-554.06-----75.5873.6123.99------
Percheron Therapeutics Ltd371.10k-14.92m8.70m8.00--0.8696--23.44-0.0149-0.01490.00040.00920.0275--0.2824---110.67-79.28-153.98-96.61-----4,021.00-3,694.96---1,093.500.0026---39.7164.80-25.19---6.74--
Invex Therapeutics Ltd461.52k-476.87k9.39m----1.79--20.35-0.0063-0.00630.00610.06980.0797--4.92---8.23-15.04-8.72-15.74-----103.33-419.12----0.00---72.9222.7470.95------
Biotron Ltd0.00-318.57k9.46m4.00--8.42-----0.0004-0.00040.000.00040.00-------43.23-86.63-206.95-112.69------------0.00------90.73------
Data as of Oct 24 2024. Currency figures normalised to Hexima Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.